Market Closed - Xetra 11:35:01 2024-04-19 am EDT 5-day change 1st Jan Change
13.26 EUR -1.41% Intraday chart for Evotec SE -3.70% -37.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis MT
Evotec, Variant Bio Launch Partnership to Develop Treatments for Fibrosis MT
Evotec Names First Chief People Officer MT
Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024 CI
Deutsche Bank raises Evotec to 'Buy' - Frustration after CEO departure overcome DP
STOXX 600 climbs over 1% on rate-cut optimism RE
Deutsche Bank Research raises Evotec to 'Buy' - Target 19 Euro DP
EVOTEC : Deutsche Bank takes a positive view ZD
U.S. Futures, European Stocks Up as ECB Signals Moving Closer to Rate Cut DJ
EVOTEC : Receives a Buy rating from Jefferies ZD
Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Sofinnova Investment, Inc., Evotec SE, venBio LLC, Apollo Health Ventures, b2venture AG, Hevolution Foundation CI
Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Hevolution Foundation, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG CI
Tubulis Technologies announced that it has received ?128 million in funding from a group of investors CI
Evotec Grants Claris Ventures Portfolio Biotech Firms Access to Testing Platform MT
EVOTEC : Warburg Research maintains a Buy rating ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
Evotec Unit, Advanced BioScience Expand Agreement to Develop Antibodies Against HIV MT
Evotec's US Unit Expands Collaboration vs HIV with Advanced BioScience Laboratories MT
EVOTEC : RBC remains its Buy rating ZD
Jefferies lowers target for Evotec to 28 Euro - 'Buy' DP
EVOTEC : Jefferies remains its Buy rating ZD
Global markets live: Crest Nicholson, Gilead, United Airlines, 3M Company, General Electric... Our Logo
EVOTEC : RBC gives a Buy rating ZD
Evotec Says Former CEO Failed to Disclose Stock Trades Over 3 Years MT
Evotec Reiterates Trading Regulations Compliance Amid Former CEO’s Late Stock Trades Disclosure MT
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.26 EUR
Average target price
25.4 EUR
Spread / Average Target
+91.55%
Consensus
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News Evotec SE
  5. Evotec Wins $9 Million German Government Funding for COVID-19 Therapy